Trending News
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- This event has passed.
17th World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC)
December 5, 2019 - December 7, 2019
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 17th year, is a unique and exciting multidisciplinary program. The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice, and highlighting the theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
Approved for AMA PRA Category 1 Credits™